Radius is a biopharmaceutical company focused on developing therapeutics agingfor the treatment of osteoporosis and other women’s health conditions. We aspire to improve the quality of life in older adults by treating age-related conditions.
Radius is committed to the development of new therapeutics for the large and underserved osteoporosis market. The Company’s lead product candidate, BA058, is in development, in both injection (BA058-SC) and transdermal (BA058-TD) methods of administration, to reduce the risk of complications associated with osteoporosis, such as fracture. In Phase 2 trials, BA058-SC has produced faster and greater bone mineral density increases at the spine and the hip. The Company also developing BA058-TD, a short wear time, transdermal form of BA058 that is delivered using a microneedle patch technology from 3M, which is intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause.